国际标准期刊号: 2155-952X

生物技术与生物材料

开放获取

我们集团组织了 3000 多个全球系列会议 每年在美国、欧洲和美国举办的活动亚洲得到 1000 多个科学协会的支持 并出版了 700+ 开放获取期刊包含超过50000名知名人士、知名科学家担任编委会成员。

开放获取期刊获得更多读者和引用
700 种期刊 15,000,000 名读者 每份期刊 获得 25,000 多名读者

索引于
  • 哥白尼索引
  • 谷歌学术
  • 夏尔巴·罗密欧
  • 打开 J 门
  • Genamics 期刊搜索
  • 学术钥匙
  • 研究圣经
  • 中国知网(CNKI)
  • 访问全球在线农业研究 (AGORA)
  • 电子期刊图书馆
  • 参考搜索
  • 哈姆达大学
  • 亚利桑那州EBSCO
  • OCLC-世界猫
  • SWB 在线目录
  • 虚拟生物学图书馆 (vifabio)
  • 普布隆斯
  • 日内瓦医学教育与研究基金会
  • 欧洲酒吧
  • ICMJE
分享此页面

抽象的

Laboratory to Bedside: Biotechnology's Place in Healthcare's Transformational Development Environment

Lianjie Miao

The current state of healthcare is shifting due to the fast developing field of biotechnology, which has the potential to revolutionize how illnesses are identified and treated. Healthcare biotechnology has been the topic of many great efforts, and our understanding of it has grown significantly. New biomedical paradigms are developing as a result of the most recent developments in genetics and molecular biology, igniting fresh research into brandnew solutions for human health and wellbeing. However, an exciting obstacle still exists in the practical translational development of revolutionary technological discoveries. Only a small number of biotech breakthroughs have led to brand-new, revolutionary treatments and technologies for healthcare. We shall describe the clinical translational development atmosphere for biotechnology in healthcare in this paper. Notable medical biotechnology achievements and translational promotions, including historical findings and novel perspectives are carefully covered. More groundbreaking biotech ideas are about to be translated into commercial products to bring about positive health gains, despite the fact that there are nevertheless numerous obstacles in the bench-to-bedside translational development process. This is being carried out with a tight multitude of collaboration among research institutes, healthcare providers, and industry partners.

免责声明: 此摘要通过人工智能工具翻译,尚未经过审核或验证。